By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Contract research4.62M139.89%
Therapeutics2.81M85.30%
Intersegment Elimination-4.13M-125.19%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States18.72M100.00%